Apple VS Masimo

Apple's workaround for the Masimo patent dispute could hurt MASI stock. But the solution—shifting blood oxygen calculations to the iPhone—is not a guaranteed win. With a reported 92% accuracy, it may struggle to impress the FDA and customers. If it fails, Masimo's stock could rebound. #Apple #Masimo #PatentLaw